Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anacetrapib add-on to statin therapy in heterozygous familial hypercholesterolemia
2011-004525-27Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing Anacetrapib + statin with Placebo + statin (2 arms). Primary endpoint: LDL-C percentage change (beta-quantification). Started Nov 2011; status: completed.
02
Drugs
anacetrapib
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on 2011-004525-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004525-27.